Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes - Wikidata - wikimedia - TriplyDB

Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes

Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes

http://www.wikidata.org/entity/Q28260324

about

Circulating glycotoxins and dietary advanced glycation endproducts: two links to inflammatory response, oxidative stress, and aging Pharmacologic Approaches Against Advanced Glycation End Products (AGEs) in Diabetic Cardiovascular Disease Advanced glycation end-products: modifiable environmental factors profoundly mediate insulin resistance Metabolic correction in the management of diabetic peripheral neuropathy: improving clinical results beyond symptom control Systemic activation of NF-κB driven luciferase activity in transgenic mice fed advanced glycation end products modified albumin.Emerging drugs for diabetic retinopathy.Reliability of lightguide spectrophotometry (O2C) for the investigation of skin tissue microvascular blood flow and tissue oxygen supply in diabetic and nondiabetic subjects.Advanced glycation end-products decreases expression of endothelial nitric oxide synthase through oxidative stress in human coronary artery endothelial cells Controlling the receptor for advanced glycation end-products to conquer diabetic vascular complications Shifting the disease management paradigm from glucose: what are the pros?Advanced glycation endproduct (AGE) accumulation and AGE receptor (RAGE) up-regulation contribute to the onset of diabetic cardiomyopathy.A gene expression signature for insulin resistance.Molecular mechanisms of vascular dysfunction and cardiovascular biomarkers in type 2 diabetes.Effect of benfotiamine on advanced glycation endproducts and markers of endothelial dysfunction and inflammation in diabetic nephropathy Acute macrovascular dysfunction in patients with type 2 diabetes induced by ingestion of advanced glycated β-lactoglobulins Glycoxidative stress and cardiovascular complications in experimentally-induced diabetes: effects of antioxidant treatment A randomized, double-blind, crossover, placebo-controlled trial of 6 weeks benfotiamine treatment on postprandial vascular function and variables of autonomic nerve function in Type 2 diabetes.Endothelial dysfunction in patients with chronic kidney disease results from advanced glycation end products (AGE)-mediated inhibition of endothelial nitric oxide synthase through RAGE activation.Diabetic patients could do as well as non-diabetic patients without inflammation on peritoneal dialysis Antioxidants and CVD in diabetes: where do we stand now.Regulation of RAGE for attenuating progression of diabetic vascular complications.Early- and advanced non-enzymatic glycation in diabetic vascular complications: the search for therapeutics.The malnutrition of obesity: micronutrient deficiencies that promote diabetes.Role of advanced glycation end products in cardiovascular disease.The AGE-breaker ALT-711 restores high blood flow-dependent remodeling in mesenteric resistance arteries in a rat model of type 2 diabetes.Benfotiamine counteracts smoking-induced vascular dysfunction in healthy smokers.Contribution of dietary advanced glycation end products (AGE) to circulating AGE: role of dietary fat Nanomedicines for Endothelial Disorders.The vascular endothelium in diabetes--a therapeutic target?Managing chronic inflammation in the aging diabetic patient with CKD by diet or sevelamer carbonate: a modern paradigm shift.The clinical relevance of assessing advanced glycation endproducts accumulation in diabetes.Dietary Advanced Glycation End Products and Their Potential Role in Cardiometabolic Disease in Children.Current concepts in targeted therapies for the pathophysiology of diabetic microvascular complications.Role of nitrosative stress in the pathogenesis of diabetic vascular dysfunction.The role of profilin-1 in endothelial cell injury induced by advanced glycation end products (AGEs)Vascular effects of advanced glycation endproducts: Clinical effects and molecular mechanisms Thiamine deficiency in diabetes mellitus and the impact of thiamine replacement on glucose metabolism and vascular disease.Preventive aspects in peripheral artery disease.Current therapeutic interventions in the glycation pathway: evidence from clinical studies.The beneficial role of thiamine in Parkinson disease.

P2860

Q24650528-284C67DC-8E0D-4F2D-8AA9-3EE01D87F78C Q26782422-943CB705-F2E6-441F-A430-E44B6F3FBEE3 Q26800114-B4347431-A48D-4A31-B066-9561A0C67C42 Q26852079-9B8D2F18-DF30-4A1B-9D93-B06E5A3AA675 Q30313434-2BF977D8-C58A-4A62-B364-FEB30264D702 Q33388498-11C45F97-22AC-4ED4-864A-7EDF5B5FD924 Q33514629-01CBFF8F-87D2-4F69-B68F-B78E2D41022D Q33582330-4F564900-6FA3-4391-AE39-822321314EB3 Q33609776-C9AA6BE7-2E0F-4750-8F75-40A8A83B5C4C Q33610665-2750A555-059F-4F3D-8A00-DBF6D5952E96 Q33691265-37A169AB-D587-406F-9D48-DED3F01A1177 Q33748389-A70B1E0B-C6A7-4C58-B7A8-64311E6BBDC4 Q34099937-525DCDE4-B881-4019-8B31-4DA300B70EDD Q34336244-EDCAAD56-ECCE-4F54-B8A6-56EBFB3FBEC5 Q34511878-D0E3E50F-C125-4C60-956F-190746C36BB2 Q34517974-1F82392F-AC9C-4EF9-BED7-2EA2B7F1E080 Q34735842-2868525E-8094-4FCD-BE5A-20871FE67428 Q34747124-63386DDD-FC5A-41FB-A52C-5F271AA28082 Q35049055-C3F6DE6D-DA7C-48CC-957E-DB359CDF3BE8 Q35201974-066801C5-E8F1-4F16-A45B-ADA1B3AAB904 Q35494903-9BDD7C2B-270B-41F1-9635-0C877F7397D0 Q35809946-DAC271AD-A054-4B5E-857F-90F01C24F745 Q35855739-F3FA3788-868D-44C5-BDB2-78D38D771FC5 Q35929112-0049715E-2C5C-41E4-93A4-862F23F93514 Q35976708-51A75C48-D097-4162-8A5B-07361FAA588D Q36317895-D6EBF6B1-4452-42B0-84EA-CA8CE2C2F871 Q36458415-18D30134-7048-434F-9FF4-4ECDC3867780 Q36651592-73C642F4-510B-4573-AD11-2CB4438297BB Q36673550-12E6B3FD-84A0-4FC7-9A4A-4F320585B736 Q36796216-BEA894B4-C0E9-4A84-A743-3532A26B8EF0 Q36942530-44B64667-B846-48DF-9535-C022F2220FF9 Q36963380-37E83837-F871-47C8-B46F-10B91D7F3F03 Q37058905-79E1AD80-DA17-4DD8-BEA5-02B53965032A Q37230827-7C4B43F9-D44E-4952-8258-B4D5F3352A73 Q37279201-8E3D7837-AD60-4AA6-B465-1CD03CAA5DE4 Q37636453-2D8B4EAB-44EE-4FE6-811B-44FF1EAFEFE4 Q37874695-16FA6E8D-1A32-4495-A78D-6B979F482E00 Q37984281-516F9482-B514-41DC-B145-D31D5C70A058 Q38070906-E2186D7C-63F8-472D-9C0D-3A55497735A3 Q38086654-CACE815D-1687-44CE-BB01-C780E44130BE

P2860

Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes

http://www.wikidata.org/entity/Q28260324

description

2006 nî lūn-bûn

@nan

2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Benfotiamine prevents macro- a ...... dividuals with type 2 diabetes

@ast

Benfotiamine prevents macro- a ...... dividuals with type 2 diabetes

@en

Benfotiamine prevents macro- a ...... dividuals with type 2 diabetes

@nl

type

label

Benfotiamine prevents macro- a ...... dividuals with type 2 diabetes

@ast

Benfotiamine prevents macro- a ...... dividuals with type 2 diabetes

@en

Benfotiamine prevents macro- a ...... dividuals with type 2 diabetes

@nl

prefLabel

Benfotiamine prevents macro- a ...... dividuals with type 2 diabetes

@ast

Benfotiamine prevents macro- a ...... dividuals with type 2 diabetes

@en

Benfotiamine prevents macro- a ...... dividuals with type 2 diabetes

@nl

P1433

Q28260324-E72ADB66-F749-4F52-85B8-3EF3F614C030

P1476

Q28260324-B120FE32-01E9-421E-9A2C-8B10E2092461

P2093

Q28260324-158ACAA6-C069-4F3F-AC45-A60264CCCBFE

Q28260324-24D352A6-D847-4092-B109-1959916F5221

Q28260324-27ECB8FA-8BBC-4971-A14F-7A40CB470E21

Q28260324-33625844-583D-4655-A034-B7DF00EF8598

Q28260324-4620A599-0AA1-4AB2-8897-C16443804BB3

Q28260324-670A0C12-5A8F-4F12-A650-AC4DCDB7D351

Q28260324-8767C6E5-AF42-4662-A923-74090A2F7711

Q28260324-8E918B7E-2DD4-47C2-8024-CEF5A7425BE3

Q28260324-9892F3A5-61F6-4847-A128-28C345B4E340

Q28260324-A2ACD32C-AB3C-413D-8F45-7E9D8C958352

P304

Q28260324-5CC32051-C373-4B0D-9203-396582AFE7A6

P31

Q28260324-9496C2C8-834D-4997-B711-92A021CE3879

P3181

Q28260324-7A3F0F22-E3A1-479C-ADC6-613E3513E5E3

P356

Q28260324-2E1FF262-2E74-4411-88D7-B5E04859BD86

P407

Q28260324-02FEC635-25AD-4D35-91E5-23AA76F31C4A

P433

Q28260324-FC58D3FA-E99D-40A8-AD06-72AB4517AC88

P478

Q28260324-08261BD0-3150-4865-9C4C-E798A581A931

P577

Q28260324-D5969033-8214-4FCD-9A90-31B167D6C146

P5875

Q28260324-7FEA1820-A9E3-4F37-92DF-AF7AB4D7FCD2

P698

Q28260324-2C74F091-352C-499C-BB68-A3709098BA9A

P921

Q28260324-78834685-E0E3-4D95-BCB2-FC027851FC27

Q28260324-FDD64B09-A848-40AF-BFD8-0CE464101AB1

P3181

P356

P1433

P1476

Benfotiamine prevents macro- a ...... dividuals with type 2 diabetes

@en

P2093

Alin Stirban

http://www.w3.org/2001/XMLSchema#string

Bernd Stratmann

http://www.w3.org/2001/XMLSchema#string

Christian Götting

http://www.w3.org/2001/XMLSchema#string

Diethelm Tschoepe

http://www.w3.org/2001/XMLSchema#string

Helen Vlassara

http://www.w3.org/2001/XMLSchema#string

Jaime Uribarri

http://www.w3.org/2001/XMLSchema#string

Knut Kleesiek

http://www.w3.org/2001/XMLSchema#string

Michaela Mueller-Roesel

http://www.w3.org/2001/XMLSchema#string

Monica Negrean

http://www.w3.org/2001/XMLSchema#string

Theodor Koschinsky

http://www.w3.org/2001/XMLSchema#string

P304

2064-71

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4168628

http://www.w3.org/2001/XMLSchema#string

P356

10.2337/DC06-0531

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P577

2006-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6852730

http://www.w3.org/2001/XMLSchema#string

P698

16936154

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes